Barclays PLC Sells 133,377 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Barclays PLC lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 38.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 215,979 shares of the company's stock after selling 133,377 shares during the quarter. Barclays PLC owned 0.26% of IDEXX Laboratories worth $89,293,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Hurley Capital LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at $29,000. Rialto Wealth Management LLC purchased a new stake in IDEXX Laboratories during the fourth quarter valued at $30,000. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories in the fourth quarter valued at about $31,000. Kestra Investment Management LLC purchased a new position in IDEXX Laboratories in the fourth quarter worth about $38,000. Finally, Crews Bank & Trust bought a new position in IDEXX Laboratories in the fourth quarter worth approximately $41,000. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Up 2.3 %

IDXX traded up $9.34 during trading on Friday, reaching $411.72. The company had a trading volume of 965,481 shares, compared to its average volume of 623,837. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $548.88. The stock has a market cap of $33.37 billion, a P/E ratio of 38.59, a PEG ratio of 3.41 and a beta of 1.50. The business has a 50 day simple moving average of $422.37 and a 200-day simple moving average of $431.22.

Analysts Set New Price Targets

IDXX has been the subject of a number of recent research reports. StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday, April 12th. Barclays upped their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Bank of America boosted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Stifel Nicolaus reduced their price objective on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research report on Monday, April 14th. Finally, Piper Sandler boosted their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories has an average rating of "Moderate Buy" and an average target price of $523.75.

Insider Transactions at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.